Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Novan to Report Second Quarter 2021 Financial Results on August 12, 2021
August 05, 2021 08:05 ET
|
Novan, Inc.
DURHAM, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2021 financial results on Thursday,...
Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
July 28, 2021 08:05 ET
|
Novan, Inc.
– Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less...
Novan Announces Inclusion in Russell Microcap® Index
June 24, 2021 08:05 ET
|
Novan, Inc.
DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that as part of the annual reconstitution of the Russell stock indexes, Novan...
Novan Announces Closing of $40 Million Public Offering of Common Stock
June 21, 2021 16:01 ET
|
Novan, Inc.
DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering...
Novan Announces Pricing of $40 Million Public Offering of Common Stock
June 17, 2021 09:00 ET
|
Novan, Inc.
DURHAM, N.C., June 17, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public offering...
Novan Announces Proposed Public Offering of Common Stock
June 16, 2021 16:01 ET
|
Novan, Inc.
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company” or “Novan”) (NASDAQ: NOVN) today announced a proposed underwritten public offering of its common stock (the “Offering”)....
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
June 11, 2021 06:30 ET
|
Novan, Inc.
– B-SIMPLE4 achieves statistical significance for the primary endpoint with p-value less than 0.0001 – – No serious adverse events related to treatment with SB206 – – Novan intends to submit New...
Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program
June 10, 2021 08:30 ET
|
Novan, Inc.
– Data indicate that berdazimer sodium prevents progression of SARS-CoV-2 infection in two independent in vivo transmission studies – – Statistically significant, dose-dependent reduction in the...
Results from Novan’s Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health
June 07, 2021 08:30 ET
|
Novan, Inc.
– Positive in vitro results demonstrate antimicrobial effect of NVN4100 against a wide variety of bacteria and suggest a promising bactericidal mode of action – – Novel in vivo canine pyoderma model...
Novan Announces 1-for-10 Reverse Stock Split
May 25, 2021 08:00 ET
|
Novan, Inc.
DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has filed a Certificate of Amendment to the Restated Certificate of...